This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
On Jan. 22, 2018 Celgene announced they had acquired JUNO.
Celgene is a large well established pharmaceutical company with a strong presence in blood cancer, and while it has no CLL drugs, it does have a promising pipeline for CLL.
JUNO is a newer smaller company that is focused exclusively on the exciting development of CAR-T and related therapy to treat different cancers, including CLL. JUNO’s newest CAR-T, JCAR017, looks very promising in CLL and other blood cancers.
For patients, hopefully this means that the strength of Celgene can help accelerate JUNO’s drugs to patients sooner, first in clinical trials, and then more broadly available through our CLL treatment teams.
Here is a link to the press release: http://ir.celgene.com/releasedetail.cfm?ReleaseID=1054833
January 23, 2018